ID   ERBB4_HUMAN             Reviewed;        1308 AA.
AC   Q15303; B7ZLD7; B7ZLE2; B7ZLE3; Q2M1W1; Q59EW4;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   02-NOV-2010, entry version 126.
DE   RecName: Full=Receptor tyrosine-protein kinase erbB-4;
DE            EC=2.7.10.1;
DE   AltName: Full=Proto-oncogene-like protein c-ErbB-4;
DE   AltName: Full=Tyrosine kinase-type cell surface receptor HER4;
DE   AltName: Full=p180erbB4;
DE   Contains:
DE     RecName: Full=ERBB4 intracellular domain;
DE              Short=4ICD;
DE              Short=E4ICD;
DE     AltName: Full=s80HER4;
DE   Flags: Precursor;
GN   Name=ERBB4; Synonyms=HER4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM JM-A CYT-1).
RC   TISSUE=Mammary carcinoma;
RX   MEDLINE=93189574; PubMed=8383326; DOI=10.1073/pnas.90.5.1746;
RA   Plowman G.D., Culouscou J.-M., Whitney G.S., Green J.M., Carlton G.W.,
RA   Foy L., Neubauer M.G., Shoyab M.;
RT   "Ligand-specific activation of HER4/p180erbB4, a fourth member of the
RT   epidermal growth factor receptor family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:1746-1750(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS JM-A CYT-1 AND JM-B CYT-1), AND
RP   PROTEOLYTIC PROCESSING.
RC   TISSUE=Fetal brain;
RX   MEDLINE=97476287; PubMed=9334263; DOI=10.1074/jbc.272.42.26761;
RA   Elenius K., Corfas G., Paul S., Choi C.J., Rio C., Plowman G.D.,
RA   Klagsbrun M.;
RT   "A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific
RT   tissue distribution and differential processing in response to phorbol
RT   ester.";
RL   J. Biol. Chem. 272:26761-26768(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS JM-A CYT-1; JM-B
RP   CYT-1; JM-A CYT-2 AND JM-B CYT-2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 401-1308 (ISOFORM JM-A
RP   CYT-2).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=10744726; DOI=10.1074/jbc.275.14.10379;
RA   Rio C., Buxbaum J.D., Peschon J.J., Corfas G.;
RT   "Tumor necrosis factor-alpha-converting enzyme is required for
RT   cleavage of erbB4/HER4.";
RL   J. Biol. Chem. 275:10379-10387(2000).
RN   [6]
RP   INTERACTION WITH DLG2; DLG3; DLG4 AND SNTB2.
RX   MEDLINE=20202681; PubMed=10725395; DOI=10.1073/pnas.070042497;
RA   Garcia R.A., Vasudevan K., Buonanno A.;
RT   "The neuregulin receptor ErbB-4 interacts with PDZ-containing proteins
RT   at neuronal synapses.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3596-3601(2000).
RN   [7]
RP   MUTAGENESIS OF LYS-751.
RX   PubMed=11390655; DOI=10.1128/MCB.21.13.4265-4275.2001;
RA   Sartor C.I., Zhou H., Kozlowska E., Guttridge K., Kawata E.,
RA   Caskey L., Harrelson J., Hynes N., Ethier S., Calvo B., Earp H.S. III;
RT   "Her4 mediates ligand-dependent antiproliferative and differentiation
RT   responses in human breast cancer cells.";
RL   Mol. Cell. Biol. 21:4265-4275(2001).
RN   [8]
RP   FUNCTION, PROTEOLYTIC PROCESSING, SUBCELLULAR LOCATION, INTERACTION
RP   WITH YAP1, AND MUTAGENESIS OF TYR-1301.
RX   PubMed=12807903; DOI=10.1074/jbc.M305597200;
RA   Komuro A., Nagai M., Navin N.E., Sudol M.;
RT   "WW domain-containing protein YAP associates with ErbB-4 and acts as a
RT   co-transcriptional activator for the carboxyl-terminal fragment of
RT   ErbB-4 that translocates to the nucleus.";
RL   J. Biol. Chem. 278:33334-33341(2003).
RN   [9]
RP   INTERACTION WITH MUC1.
RX   PubMed=12939402;
RA   Li Y., Yu W.-H., Ren J., Chen W., Huang L., Kharbanda S., Loda M.,
RA   Kufe D.;
RT   "Heregulin targets gamma-catenin to the nucleolus by a mechanism
RT   dependent on the DF3/MUC1 oncoprotein.";
RL   Mol. Cancer Res. 1:765-775(2003).
RN   [10]
RP   INTERACTION WITH WWOX, DOMAIN, AND MUTAGENESIS OF TYR-1035 AND
RP   TYR-1301.
RX   PubMed=16061658; DOI=10.1158/0008-5472.CAN-05-1150;
RA   Aqeilan R.I., Donati V., Palamarchuk A., Trapasso F., Kaou M.,
RA   Pekarsky Y., Sudol M., Croce C.M.;
RT   "WW domain-containing proteins, WWOX and YAP, compete for interaction
RT   with ErbB-4 and modulate its transcriptional function.";
RL   Cancer Res. 65:6764-6772(2005).
RN   [11]
RP   PROTEOLYTIC PROCESSING, AND MUTAGENSIS OF VAL-675.
RX   PubMed=15746097; DOI=10.1074/jbc.M412457200;
RA   Vidal G.A., Naresh A., Marrero L., Jones F.E.;
RT   "Presenilin-dependent gamma-secretase processing regulates multiple
RT   ERBB4/HER4 activities.";
RL   J. Biol. Chem. 280:19777-19783(2005).
RN   [12]
RP   INTERACTION WITH CBFA2T3.
RX   PubMed=16815842; DOI=10.1074/jbc.M603998200;
RA   Linggi B., Carpenter G.;
RT   "ErbB-4 s80 intracellular domain abrogates ETO2-dependent
RT   transcriptional repression.";
RL   J. Biol. Chem. 281:25373-25380(2006).
RN   [13]
RP   FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=16251361; DOI=10.1091/mbc.E05-05-0402;
RA   Maatta J.A., Sundvall M., Junttila T.T., Peri L., Laine V.J.,
RA   Isola J., Egeblad M., Elenius K.;
RT   "Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4
RT   isoform promote ligand-independent survival and cancer cell growth.";
RL   Mol. Biol. Cell 17:67-79(2006).
RN   [14]
RP   FUNCTION OF ERBB4 INTRACELLULAR DOMAIN, PROTEOLYTIC PROCESSING,
RP   SUBCELLULAR LOCATION, UBIQUITINATION OF ERBB4 INTRACELLULAR DOMAIN,
RP   AND MUTAGENSIS OF VAL-675; LYS-751; ARG-992; LYS-995 AND ASP-1000.
RX   PubMed=17638867; DOI=10.1158/0008-5472.CAN-06-4145;
RA   Strunk K.E., Husted C., Miraglia L.C., Sandahl M., Rearick W.A.,
RA   Hunter D.M., Earp H.S. III, Muraoka-Cook R.S.;
RT   "HER4 D-box sequences regulate mitotic progression and degradation of
RT   the nuclear HER4 cleavage product s80HER4.";
RL   Cancer Res. 67:6582-6590(2007).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-733, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Lung carcinoma;
RX   PubMed=18083107; DOI=10.1016/j.cell.2007.11.025;
RA   Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J.,
RA   Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L.,
RA   Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J.,
RA   Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X.,
RA   Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.;
RT   "Global survey of phosphotyrosine signaling identifies oncogenic
RT   kinases in lung cancer.";
RL   Cell 131:1190-1203(2007).
RN   [16]
RP   FUNCTION OF E4ICD, PHOSPHORYLATION, SUBCELLULAR LOCATION OF E4ICD, AND
RP   MUTAGENESIS OF LYS-751.
RX   PubMed=17486069; DOI=10.1038/sj.onc.1210501;
RA   Sundvall M., Peri L., Maatta J.A., Tvorogov D., Paatero I.,
RA   Savisalo M., Silvennoinen O., Yarden Y., Elenius K.;
RT   "Differential nuclear localization and kinase activity of alternative
RT   ErbB4 intracellular domains.";
RL   Oncogene 26:6905-6914(2007).
RN   [17]
RP   INTERACTION WITH NEDD4, SUBCELLULAR LOCATION, AND UBIQUITINATION OF
RP   E4ICD1.
RX   PubMed=19193720; DOI=10.1096/fj.08-121947;
RA   Zeng F., Xu J., Harris R.C.;
RT   "Nedd4 mediates ErbB4 JM-a/CYT-1 ICD ubiquitination and degradation in
RT   MDCK II cells.";
RL   FASEB J. 23:1935-1945(2009).
RN   [18]
RP   INTERACTION WITH WWP1, AND MUTAGENESIS OF TYR-1056 AND TYR-1301.
RX   PubMed=19561640; DOI=10.1038/onc.2009.162;
RA   Li Y., Zhou Z., Alimandi M., Chen C.;
RT   "WW domain containing E3 ubiquitin protein ligase 1 targets the full-
RT   length ErbB4 for ubiquitin-mediated degradation in breast cancer.";
RL   Oncogene 28:2948-2958(2009).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 26-641, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-138; ASN-174; ASN-253; ASN-358; ASN-410; ASN-473;
RP   ASN-495 AND ASN-576.
RX   PubMed=16203964; DOI=10.1073/pnas.0507591102;
RA   Bouyain S., Longo P.A., Li S., Ferguson K.M., Leahy D.J.;
RT   "The extracellular region of ErbB4 adopts a tethered conformation in
RT   the absence of ligand.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:15024-15029(2005).
RN   [20]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-140 AND TYR-303.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Specifically binds and is activated by neuregulins, NRG-
CC       2, NRG-3, heparin-binding EGF-like growth factor, betacellulin and
CC       NTAK. Interaction with these factors induces cell differentiation.
CC       Not activated by EGF, TGF-A, and amphiregulin. The C-terminal
CC       fragment (CTF) of isoform JMA-A CYT-2 (containing E4ICD2) can
CC       stimulate transcription in the presence of YAP1. ERBB4
CC       intracellular domain is involved in the regulation of cell growth.
CC       Conflicting reports are likely due at least in part to the
CC       opposing effects of the isoform-specific and nuclear-translocated
CC       ERBB4 intracellular domains (E4ICD1 and E4ICD2). Overexpression
CC       studies in epithelium show growth inhibition using E4ICD1 and
CC       increased proliferation using E4ICD2. E4ICD2 has greater in vitro
CC       kinase activity than E4ICD1. The kinase activity is required for
CC       the nuclear translocation of E4ICD2.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate.
CC   -!- SUBUNIT: Homodimer or heterodimer with each of the other ERBB
CC       receptors (Potential). Interacts with PDZ domains of DLG2, DLG3,
CC       DLG4 and the syntrophin SNTB2. Interacts with CBFA2T3 and MUC1.
CC       Interacts (via PPxy motifs) with WWOX. Isoform JM-A CYT-2
CC       interacts (via PPxY motif 3) with isoform 1 and isoform 2 of YAP1
CC       (via WW domain 1). Isoform JM-A CYT-1 and isoform JM-B CYT-1
CC       interact with WWP1.
CC   -!- INTERACTION:
CC       P78352:DLG4; NbExp=3; IntAct=EBI-80371, EBI-80389;
CC       P00533:EGFR; NbExp=2; IntAct=EBI-80371, EBI-297353;
CC       P04626:ERBB2; NbExp=2; IntAct=EBI-80371, EBI-641062;
CC       P21860:ERBB3; NbExp=3; IntAct=EBI-80371, EBI-720706;
CC       Q05586:GRIN1; NbExp=1; IntAct=EBI-80371, EBI-998542;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane
CC       protein.
CC   -!- SUBCELLULAR LOCATION: ERBB4 intracellular domain: Nucleus.
CC       Note=Following proteolytical processing E4ICD (E4ICD1 or E4ICD2
CC       generated from the respective isoforms) is translocated to the
CC       nucleus. Significantly more E4ICD2 than E4ICD1 is found in the
CC       nucleus. E4ICD2 colocalizes with YAP1 in the nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=JM-A CYT-1;
CC         IsoId=Q15303-1; Sequence=Displayed;
CC         Note=Proteolytical processing generates E4ICD1 (s80Cyt1);
CC       Name=JM-B CYT-1;
CC         IsoId=Q15303-2; Sequence=VSP_002895;
CC       Name=JM-A CYT-2;
CC         IsoId=Q15303-3; Sequence=VSP_022148;
CC         Note=Proteolytical processing generates E4ICD2 (s80Cyt2);
CC       Name=JM-B CYT-2;
CC         IsoId=Q15303-4; Sequence=VSP_002895, VSP_022148;
CC   -!- TISSUE SPECIFICITY: Expressed at highest levels in brain, heart,
CC       kidney, in addition to skeletal muscle, parathyroid, cerebellum,
CC       pituitary, spleen, testis and breast. Lower levels in thymus,
CC       lung, salivary gland, and pancreas. Isoform JM-A CYT-1 and isoform
CC       JM-B CYT-1 are expressed in cerebellum, but only the isoform JM-B
CC       is expressed in the heart.
CC   -!- PTM: Isoform JM-A CYT-1 and isoform JM-A CYT-2 but not isoform JM-
CC       B CYT-1 and isoform JM-B CYT-2 are processed by ADAM17.
CC       Proteolytic processing in response to ligand or 12-O-
CC       tetradecanoylphorbol-13-acetate stimulation results in the
CC       production of 120 kDa soluble receptor forms and intermediate
CC       membrane-anchored 80 kDa fragments (m80HER4), which are further
CC       processed by a presenilin-dependent gamma-secretase to release the
CC       respective cytoplasmic intracellular domain E4ICD (either
CC       E4ICD1/s80Cyt1 or E4ICD2/s80Cyt2). Membrane-anchored 80 kDa
CC       fragments of the processed isoform JM-A CYT-1 are more readily
CC       degraded by the proteasome than fragments of isoform JM-A CYT-2
CC       suggesting a prevalence of E4ICD2 over E4ICD1.
CC   -!- PTM: Ligand-binding increases phosphorylation on tyrosine
CC       residues. Isoform JM-A CYT-2 is constitutively phosphorylated on
CC       tyrosine residues in a ligand-independent manner. E4ICD2 but not
CC       E4ICD1 is phosphorylated on tyrosine residues.
CC   -!- PTM: Ubiquitinated. The ERBB4 intracellular domain is
CC       ubiquitinated and targeted to proteosomal degradation during
CC       mitosis mediated by the APC/C complex. Isoform JM-A CYT-1 and
CC       isoform JM-B CYT-1 are ubiquitinated by WWP1. The ERBB4
CC       intracellular domain (E4ICD1) is ubiquitinated, and this involves
CC       NEDD4.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. EGF receptor subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L07868; AAB59446.1; -; mRNA.
DR   EMBL; BC112199; AAI12200.1; -; mRNA.
DR   EMBL; BC143741; AAI43742.1; -; mRNA.
DR   EMBL; BC143747; AAI43748.1; -; mRNA.
DR   EMBL; BC143749; AAI43750.1; -; mRNA.
DR   EMBL; AB209697; BAD92934.1; -; mRNA.
DR   IPI; IPI00016371; -.
DR   IPI; IPI00215722; -.
DR   IPI; IPI00816395; -.
DR   IPI; IPI00969544; -.
DR   PIR; A47253; A47253.
DR   RefSeq; NP_001036064.1; -.
DR   RefSeq; NP_005226.1; -.
DR   UniGene; Hs.390729; -.
DR   PDB; 2AHX; X-ray; 2.40 A; A/B=26-641.
DR   PDB; 2R4B; X-ray; 2.40 A; A/B=690-999.
DR   PDB; 3BBT; X-ray; 2.80 A; B/D=702-1029.
DR   PDB; 3BBW; X-ray; 4.00 A; A/B=702-1029.
DR   PDB; 3BCE; X-ray; 2.50 A; A/B/C=702-1029.
DR   PDBsum; 2AHX; -.
DR   PDBsum; 2R4B; -.
DR   PDBsum; 3BBT; -.
DR   PDBsum; 3BBW; -.
DR   PDBsum; 3BCE; -.
DR   ProteinModelPortal; Q15303; -.
DR   DIP; DIP-29650N; -.
DR   DIP; DIP-29850N; -.
DR   DIP; DIP-6094N; -.
DR   IntAct; Q15303; 19.
DR   MINT; MINT-125091; -.
DR   STRING; Q15303; -.
DR   PhosphoSite; Q15303; -.
DR   PRIDE; Q15303; -.
DR   Ensembl; ENST00000342788; ENSP00000342235; ENSG00000178568.
DR   Ensembl; ENST00000402597; ENSP00000385565; ENSG00000178568.
DR   Ensembl; ENST00000436443; ENSP00000403204; ENSG00000178568.
DR   GeneID; 2066; -.
DR   KEGG; hsa:2066; -.
DR   UCSC; uc002veg.1; human.
DR   UCSC; uc002veh.1; human.
DR   CTD; 2066; -.
DR   GeneCards; GC02M212210; -.
DR   H-InvDB; HIX0030012; -.
DR   HGNC; HGNC:3432; ERBB4.
DR   HPA; CAB000276; -.
DR   HPA; CAB025522; -.
DR   HPA; HPA012016; -.
DR   MIM; 600543; gene.
DR   PharmGKB; PA27847; -.
DR   eggNOG; prNOG15425; -.
DR   HOGENOM; HBG445128; -.
DR   HOVERGEN; HBG000490; -.
DR   InParanoid; Q15303; -.
DR   OMA; CYADTIH; -.
DR   OrthoDB; EOG9KPWX4; -.
DR   PhylomeDB; Q15303; -.
DR   BRENDA; 2.7.10.1; 247.
DR   NextBio; 8397; -.
DR   PMAP-CutDB; Q15303; -.
DR   ArrayExpress; Q15303; -.
DR   Bgee; Q15303; -.
DR   CleanEx; HS_ERBB4; -.
DR   Genevestigator; Q15303; -.
DR   GermOnline; ENSG00000178568; Homo sapiens.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0016021; C:integral to membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005515; F:protein binding; IPI:UniProtKB.
DR   GO; GO:0004716; F:receptor signaling protein tyrosine kinase ...; IEA:InterPro.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kin...; TAS:ProtInc.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IEA:InterPro.
DR   GO; GO:0045449; P:regulation of transcription; IEA:UniProtKB-KW.
DR   GO; GO:0006350; P:transcription; IEA:UniProtKB-KW.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kin...; IEA:InterPro.
DR   InterPro; IPR000494; EGF_rcpt_L.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr-Pkinase.
DR   InterPro; IPR016245; Tyr_kinase_EGF/ERB/XmrK_rcpt.
DR   InterPro; IPR020635; Tyr_Pkinase_cat_dom.
DR   InterPro; IPR020685; Tyr_prot_kinase.
DR   InterPro; IPR008266; Tyr_prot_kinase_AS.
DR   InterPro; IPR020690; Tyr_prot_kinase_rcpt_ErbB4.
DR   PANTHER; PTHR23256; Tyr_prot_kinase; 1.
DR   PANTHER; PTHR23256:SF24; Tyr_prot_kinase_rcpt_erbB4; 1.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000619; TyrPK_EGF-R; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00261; FU; 5.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF57184; Grow_fac_recept; 2.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; ATP-binding;
KW   Complete proteome; Disulfide bond; Glycoprotein; Kinase; Membrane;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism; Receptor;
KW   Repeat; Signal; Transcription; Transcription regulation; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL        1     25       Potential.
FT   CHAIN        26   1308       Receptor tyrosine-protein kinase erbB-4.
FT                                /FTId=PRO_0000016674.
FT   CHAIN         ?   1308       ERBB4 intracellular domain.
FT                                /FTId=PRO_0000396797.
FT   TOPO_DOM     26    651       Extracellular (Potential).
FT   TRANSMEM    652    675       Potential.
FT   TOPO_DOM    676   1308       Cytoplasmic (Potential).
FT   DOMAIN      718    985       Protein kinase.
FT   NP_BIND     724    732       ATP (By similarity).
FT   MOTIF      1032   1035       PPxY motif 1.
FT   MOTIF      1053   1056       PPxY motif 2.
FT   MOTIF      1298   1301       PPxY motif 3.
FT   MOTIF      1306   1308       PDZ-binding.
FT   COMPBIAS    186    334       Cys-rich.
FT   COMPBIAS    496    633       Cys-rich.
FT   ACT_SITE    843    843       Proton acceptor (By similarity).
FT   BINDING     751    751       ATP (By similarity).
FT   MOD_RES     733    733       Phosphotyrosine.
FT   MOD_RES    1162   1162       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES    1188   1188       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES    1258   1258       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   MOD_RES    1284   1284       Phosphotyrosine; by autocatalysis (By
FT                                similarity).
FT   CARBOHYD    138    138       N-linked (GlcNAc...).
FT   CARBOHYD    174    174       N-linked (GlcNAc...).
FT   CARBOHYD    181    181       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    253    253       N-linked (GlcNAc...).
FT   CARBOHYD    358    358       N-linked (GlcNAc...).
FT   CARBOHYD    410    410       N-linked (GlcNAc...).
FT   CARBOHYD    473    473       N-linked (GlcNAc...).
FT   CARBOHYD    495    495       N-linked (GlcNAc...).
FT   CARBOHYD    548    548       N-linked (GlcNAc...) (Potential).
FT   CARBOHYD    576    576       N-linked (GlcNAc...).
FT   CARBOHYD    620    620       N-linked (GlcNAc...) (Potential).
FT   DISULFID     29     56
FT   DISULFID    156    186
FT   DISULFID    189    197
FT   DISULFID    193    205
FT   DISULFID    213    221
FT   DISULFID    217    229
FT   DISULFID    230    238
FT   DISULFID    234    246
FT   DISULFID    249    258
FT   DISULFID    262    289
FT   DISULFID    293    304
FT   DISULFID    308    323
FT   DISULFID    326    330
FT   DISULFID    503    512
FT   DISULFID    507    520
FT   DISULFID    523    532
FT   DISULFID    536    552
FT   DISULFID    555    569
FT   DISULFID    559    577
FT   DISULFID    580    589
FT   DISULFID    593    614
FT   DISULFID    617    625
FT   DISULFID    621    633
FT   VAR_SEQ     626    648       NGPTSHDCIYYPWTGHSTLPQHA -> IGSSIEDCIGLMD
FT                                (in isoform JM-B CYT-1 and isoform JM-B
FT                                CYT-2).
FT                                /FTId=VSP_002895.
FT   VAR_SEQ    1046   1061       Missing (in isoform JM-A CYT-2 and
FT                                isoform JM-B CYT-2).
FT                                /FTId=VSP_022148.
FT   VARIANT     140    140       T -> I (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042113.
FT   VARIANT     303    303       S -> Y (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_042114.
FT   MUTAGEN     675    675       V->A: Abolishes proteolytic processing
FT                                and nuclear localization.
FT   MUTAGEN     751    751       K->R: Abolishes kinase activity.
FT                                Abolishes phosphorylation, proteolytic
FT                                processing and nuclear localization.
FT   MUTAGEN     992    992       R->A: Abolishes APC/C-mediated
FT                                degradation; when associated with A-995
FT                                and A-1000.
FT   MUTAGEN     995    995       L->A: Abolishes APC/C-mediated
FT                                degradation; when associated with A-992
FT                                and A-1000.
FT   MUTAGEN    1000   1000       D->A: Abolishes APC/C-mediated
FT                                degradation; when associated with A-992
FT                                and A-995.
FT   MUTAGEN    1035   1035       Y->A: No effect on interaction with WWOX.
FT                                Abolishes interaction with WWOX; when
FT                                associated with A-1301.
FT   MUTAGEN    1056   1056       Y->A: Abolishes interaction with NEDD4
FT                                and impairs ubiquitination. Promotes
FT                                nuclear translocation of ERBB4
FT                                intracellular domain E4ICD1.
FT   MUTAGEN    1056   1056       Y->F: Abolishes interaction with WWP1;
FT                                when associated with F-1301.
FT   MUTAGEN    1301   1301       Y->A: Abolishes interaction with NEDD4
FT                                and impairs ubiquitination.
FT   MUTAGEN    1301   1301       Y->A: No effect on interaction with WWOX.
FT                                Abolishes interaction with WWOX; when
FT                                associated with A-1035. Loss of
FT                                interaction with YAP1 and stimulation of
FT                                transcription.
FT   MUTAGEN    1301   1301       Y->F: Abolishes interaction with WWP1;
FT                                when associated with F-1056.
FT   STRAND       28     30
FT   HELIX        42     53
FT   STRAND       57     61
FT   STRAND       63     67
FT   HELIX        75     79
FT   STRAND       82     85
FT   STRAND       87     91
FT   STRAND       95     98
FT   TURN        112    114
FT   STRAND      115    120
FT   STRAND      133    135
FT   STRAND      144    150
FT   HELIX       158    160
FT   HELIX       163    165
FT   HELIX       173    175
FT   STRAND      176    178
FT   TURN        191    193
FT   STRAND      197    201
FT   HELIX       202    204
FT   STRAND      221    225
FT   HELIX       226    228
FT   STRAND      234    242
FT   STRAND      245    254
FT   STRAND      257    261
FT   STRAND      265    269
FT   TURN        270    273
FT   STRAND      274    277
FT   STRAND      283    285
FT   STRAND      288    292
FT   STRAND      298    300
FT   STRAND      303    307
FT   STRAND      312    317
FT   STRAND      320    325
FT   STRAND      333    335
FT   HELIX       340    342
FT   TURN        350    352
FT   HELIX       353    356
FT   STRAND      360    364
FT   STRAND      366    368
FT   HELIX       370    374
FT   HELIX       377    379
FT   HELIX       386    394
FT   STRAND      397    400
FT   STRAND      402    405
FT   HELIX       415    417
FT   STRAND      432    438
FT   STRAND      455    461
FT   HELIX       469    471
FT   HELIX       474    476
FT   STRAND      479    482
FT   STRAND      485    487
FT   STRAND      489    491
FT   HELIX       493    497
FT   TURN        498    500
FT   STRAND      512    516
FT   STRAND      519    528
FT   STRAND      531    534
FT   STRAND      537    543
FT   STRAND      545    548
FT   STRAND      551    554
FT   STRAND      568    573
FT   STRAND      576    585
FT   STRAND      588    592
FT   STRAND      595    608
FT   STRAND      612    616
FT   STRAND      625    629
FT   HELIX       715    717
FT   STRAND      718    729
FT   STRAND      731    737
FT   STRAND      746    752
FT   HELIX       762    773
FT   STRAND      783    787
FT   STRAND      789    791
FT   STRAND      793    797
FT   HELIX       804    810
FT   HELIX       812    814
FT   HELIX       817    836
FT   HELIX       846    848
FT   STRAND      849    853
FT   STRAND      856    859
FT   HELIX       864    869
FT   HELIX       884    886
FT   HELIX       889    893
FT   HELIX       899    914
FT   TURN        920    923
FT   TURN        926    928
FT   HELIX       929    934
FT   HELIX       947    955
FT   HELIX       961    963
FT   HELIX       967    977
FT   HELIX       981    983
SQ   SEQUENCE   1308 AA;  146808 MW;  5E4AE80985D88761 CRC64;
     MKPATGLWVW VSLLVAAGTV QPSDSQSVCA GTENKLSSLS DLEQQYRALR KYYENCEVVM
     GNLEITSIEH NRDLSFLRSV REVTGYVLVA LNQFRYLPLE NLRIIRGTKL YEDRYALAIF
     LNYRKDGNFG LQELGLKNLT EILNGGVYVD QNKFLCYADT IHWQDIVRNP WPSNLTLVST
     NGSSGCGRCH KSCTGRCWGP TENHCQTLTR TVCAEQCDGR CYGPYVSDCC HRECAGGCSG
     PKDTDCFACM NFNDSGACVT QCPQTFVYNP TTFQLEHNFN AKYTYGAFCV KKCPHNFVVD
     SSSCVRACPS SKMEVEENGI KMCKPCTDIC PKACDGIGTG SLMSAQTVDS SNIDKFINCT
     KINGNLIFLV TGIHGDPYNA IEAIDPEKLN VFRTVREITG FLNIQSWPPN MTDFSVFSNL
     VTIGGRVLYS GLSLLILKQQ GITSLQFQSL KEISAGNIYI TDNSNLCYYH TINWTTLFST
     INQRIVIRDN RKAENCTAEG MVCNHLCSSD GCWGPGPDQC LSCRRFSRGR ICIESCNLYD
     GEFREFENGS ICVECDPQCE KMEDGLLTCH GPGPDNCTKC SHFKDGPNCV EKCPDGLQGA
     NSFIFKYADP DRECHPCHPN CTQGCNGPTS HDCIYYPWTG HSTLPQHART PLIAAGVIGG
     LFILVIVGLT FAVYVRRKSI KKKRALRRFL ETELVEPLTP SGTAPNQAQL RILKETELKR
     VKVLGSGAFG TVYKGIWVPE GETVKIPVAI KILNETTGPK ANVEFMDEAL IMASMDHPHL
     VRLLGVCLSP TIQLVTQLMP HGCLLEYVHE HKDNIGSQLL LNWCVQIAKG MMYLEERRLV
     HRDLAARNVL VKSPNHVKIT DFGLARLLEG DEKEYNADGG KMPIKWMALE CIHYRKFTHQ
     SDVWSYGVTI WELMTFGGKP YDGIPTREIP DLLEKGERLP QPPICTIDVY MVMVKCWMID
     ADSRPKFKEL AAEFSRMARD PQRYLVIQGD DRMKLPSPND SKFFQNLLDE EDLEDMMDAE
     EYLVPQAFNI PPPIYTSRAR IDSNRSEIGH SPPPAYTPMS GNQFVYRDGG FAAEQGVSVP
     YRAPTSTIPE APVAQGATAE IFDDSCCNGT LRKPVAPHVQ EDSSTQRYSA DPTVFAPERS
     PRGELDEEGY MTPMRDKPKQ EYLNPVEENP FVSRRKNGDL QALDNPEYHN ASNGPPKAED
     EYVNEPLYLN TFANTLGKAE YLKNNILSMP EKAKKAFDNP DYWNHSLPPR STLQHPDYLQ
     EYSTKYFYKQ NGRIRPIVAE NPEYLSEFSL KPGTVLPPPP YRHRNTVV
//
